OncoMatch/Clinical Trials/NCT06925516

A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

Is NCT06925516 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Apatinib and Adebrelimab in Combination With chemotherapy for intrahepatic cholangiocarcinoma (icc).

Phase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06925516Data as of May 2026

Treatment: Apatinib and Adebrelimab in Combination With chemotherapy — The study aims to evaluate the efficacy and safety of Apatinib and Adebrelimab in Combination With chemotherapy in patients with advanced intrahepatic cholangiocarcinoma (ICC)

Check if I qualify

Extracted eligibility criteria

Cancer type

Cholangiocarcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: immune checkpoint inhibitor

Previous treatment with Immune Checkpoint Inhibitors: Prior use of any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints), including anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies (including topical use).

Lab requirements

Liver function

child-pugh class: grade a

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify